CINECA IRIS Institutional Research Information System

NICOLINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.973
AS - Asia 6.710
EU - Europa 4.096
SA - Sud America 786
AF - Africa 220
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 2
Totale 24.799
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.523
CN - Cina 2.277
SG - Singapore 2.049
IT - Italia 1.232
HK - Hong Kong 1.205
BR - Brasile 711
SE - Svezia 636
BG - Bulgaria 564
CA - Canada 398
UA - Ucraina 374
TR - Turchia 363
DE - Germania 329
KR - Corea 318
VN - Vietnam 251
FI - Finlandia 245
RU - Federazione Russa 226
GB - Regno Unito 196
CH - Svizzera 142
CI - Costa d'Avorio 116
IN - India 63
FR - Francia 41
BD - Bangladesh 32
AR - Argentina 25
JP - Giappone 25
MX - Messico 25
IQ - Iraq 24
SN - Senegal 22
ZA - Sudafrica 19
BE - Belgio 17
BJ - Benin 16
SA - Arabia Saudita 15
UZ - Uzbekistan 14
AT - Austria 13
CZ - Repubblica Ceca 12
NL - Olanda 12
PK - Pakistan 12
EC - Ecuador 11
CO - Colombia 10
ID - Indonesia 10
MA - Marocco 10
VE - Venezuela 10
AU - Australia 9
ES - Italia 9
PL - Polonia 9
PY - Paraguay 9
GR - Grecia 8
JO - Giordania 7
LT - Lituania 6
TN - Tunisia 6
EG - Egitto 5
HU - Ungheria 5
IR - Iran 5
JM - Giamaica 5
KE - Kenya 5
NP - Nepal 5
DK - Danimarca 4
IL - Israele 4
OM - Oman 4
RO - Romania 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
AE - Emirati Arabi Uniti 3
BB - Barbados 3
BS - Bahamas 3
IE - Irlanda 3
KZ - Kazakistan 3
LB - Libano 3
MU - Mauritius 3
PA - Panama 3
PE - Perù 3
TH - Thailandia 3
AO - Angola 2
BW - Botswana 2
CL - Cile 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
EU - Europa 2
KG - Kirghizistan 2
LY - Libia 2
NI - Nicaragua 2
PS - Palestinian Territory 2
RS - Serbia 2
TW - Taiwan 2
AL - Albania 1
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
EE - Estonia 1
FJ - Figi 1
GA - Gabon 1
GE - Georgia 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
Totale 24.782
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.423
Ashburn 1.256
Ann Arbor 1.238
Hong Kong 1.202
Singapore 1.070
Chandler 967
Fairfield 918
Houston 884
Sofia 563
Dallas 542
Jacksonville 485
Milan 473
Shanghai 473
Beijing 428
Santa Clara 407
Seattle 377
Hefei 374
Ottawa 367
Wilmington 354
Cambridge 336
New York 336
Seoul 316
Nanjing 260
Izmir 258
Boardman 242
Princeton 229
Lawrence 220
Medford 214
Des Moines 165
Bern 139
Los Angeles 117
Abidjan 116
Dearborn 101
Istanbul 93
Nanchang 90
Buffalo 79
Jüchen 75
Redondo Beach 74
Dong Ket 71
Florence 66
São Paulo 57
Kunming 56
Serra 56
San Diego 44
Shenyang 44
Chicago 38
Munich 36
Hebei 34
Ogden 34
The Dalles 34
Boulder 33
Council Bluffs 33
Rome 33
Tianjin 33
Ho Chi Minh City 32
Columbus 31
Falls Church 28
Changsha 27
Rio de Janeiro 26
Hangzhou 23
Redwood City 23
Dakar 22
London 22
Pune 22
Guangzhou 21
Lancaster 20
Jiaxing 19
Frankfurt am Main 18
Norwalk 18
Pisa 18
Tokyo 18
Brussels 17
Düsseldorf 17
Orange 17
Auburn Hills 16
Cotonou 16
Brasília 14
Hanoi 14
Phoenix 14
Turku 14
Fuzhou 13
Lanzhou 13
San Jose 13
Vienna 13
Washington 13
Curitiba 12
Jinan 12
Salvador 11
Belo Horizonte 10
Changchun 10
Dhaka 10
Genoa 10
Johannesburg 10
Porto Alegre 10
Tashkent 10
Anguillara Sabazia 9
Detroit 9
Nuremberg 9
Brooklyn 8
Helsinki 8
Totale 18.703
Salva come PNG Salva come JPEG
Nome #
Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. 216
Are risk factors common to thyroid cancer and nodule? A forty years observational time-trend study 197
T cell-mediated immunity, eosinophils, sIL-2R, neopterin and interleukins 4, 6, 10, 12 in metastatic renal and colorectal cancer patients (pts) cyclically treated with low subcutaneous (s.c.) rIL-2 194
Effect of pulsed electromagnetic field stimulation on knee cartilage, subchondral and epyphiseal trabecular bone of aged Dunkin Hartley guinea pigs 192
Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. 191
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma 188
Manual lymphatic drainage for chronic post-mastectomy lymphoedema treatment 187
Molecular markers in breast cancer: no longer a “free” run from laboratory to the clinic 181
Quantification of Blood Dendritic Cells in Colorectal Cancer Patients During the Course of Disease 177
Early diagnosis and treatment of breast cancer relapses 173
Cancer stem cells: perspectives of new therapeutical approaches for breast cancer 173
A rationale non-invasive schedule with tumor markers and instrumental exsaminations for “early” detection of bone metastases in breast cancer 169
Additional 5-FU-LV significantly increases survival in gastrointestinal cancer 169
Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment. 168
Accuracy of an individual reference limit (IRL) during intensive post-operative monitoring of disease-free breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel 167
An iron regulatory gene signature in breast cancer: More than a prognostic genetic profile? 163
Prolonged survival by “early” salvage treatment of breast cancer patients: a retrospective six year study 161
Defining the critical hurdles in cancer immunotherapy. 156
A meta-analysis of the performance of serum tumour markers levels for early signalling distant metastases during post-operative follow-up of disease-free breast cancer patients 155
Bone scintigraphy and tumor markers in the post-operative follow-up of breast, colorectal, prostate and renal cancer 155
Stem cells: their role in breast cancer development and resistance to treatment. 155
Tumor markers increase the diagnostic accuracy of skeletal metastases in breast cancer patients 153
Pilot study with subcutaneous (s.c.) low dose rIL-2 cyclically given in addition to 5-FU and leucovorin (LV) in metastatic colorectal cancer 149
Reducing radiological imaging during post-operative monitoring of breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel and an individual reference limit (IRL) 149
Cytometric evaluation of mitogenic proliferation response to phytohemagglutinin (PHA) and NK cytotoxic activity of peripheral blood lymphocytes in patients (pts) mastectomized for breast cancer 147
Criteria to use serum tumour marker levels for early signalling distant metastases durino post-operative follow-up of disease-free breast cancer patients: laboratori and clinical aspects. 145
Lymphopressotherapy in chronic postmastectomy lymphedema 142
Cytometric evaluation of mitogenic proliferation response to phytohemagglutinin and NK cytotoxic activity of peripheral blood lymphocytes in patients mastectomized for breast cancer 142
Tumoral markers in the kidney cancer: preliminary results 142
Urinary markers of bone resorption in breast cancer patients 142
A rational non invasive schedule with tumor markers, bone scanning (BS) and "aimed" computed tomography (CT) or skeletal x - ray for "early" detection of bone metastases in breast cancer 142
Cell mediated immunity in disease free breast cancer patients 142
Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate. 142
CEA, TPA, GICA, CA 72-4 and CA 195 and their associations in the post-operative follow-up of colorectal cancer 141
Cell mediated immunity (CMI) in breast cancer patients at the relapse 141
Microcirculation in chronic post-mastectomy lymphoedem 141
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect 141
Postoperative monitoring of breast cancer patients with tumor markers 140
Cell mediated immunity (CMI) in non relapsed breast cancer patients 138
T-cell mediated immunity (CMI) and B lymphocytes in breast cancer patients after mastectomy 137
Comparison of Ca 549 and TPS usefulness with CEA, TPA and Ca 15.3 in the post-operative follow-up of breast cancer patients 136
Impact on survival of "early" detection of colorectal cancer relapses with tumor markers 136
Prognostic indices of overall survival (OS) and response to TAM and MAP in metastatic breast cancer patients 135
Evaluation of CEA, TPA, Ca 15.3, Ca 549 and TPS in the monitoring of metastatic breast cancer 135
Circulating tumor cells (CTCs) in breast cancer post-operative follow-up: a preliminary comparison with serum CEA-TPA-CA15.3 tumor marker (TM) panel based monitoring. 135
CEA, TPA, GICA, CA 72-4 and CA 195 in the post-operative follow-up of colorectal cancer 134
Large needle aspiration biopsy histology for the preoperative selection of the palpable thyroid nodule diagnosed by FNA cytology as microfollicular nodule, microfollicular nodule with atypical cells or suspected cancer 134
Cyclic beta-interferon-interleukin-2 sequence in addition to antiestrogens significantly prolongs survival of endocrine dependent metastatic breast cancer patients 134
Large needle aspiration biopsy (LNAB) of palpable thyroid nodules refines the two FNA cytological diagnoses of microfollicular nodule and suspected cancer 133
Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor biology 133
RELATIONSHIP AMONG CIRCULATING LEVELS OF THYROID HORMONES TSH AND TBG AFTER THYROIDECTOMY 132
A rationale follow-up with CEA-TPA-CA15.3 tumor marker panel strongly decreases the conventional instrumental examinations to monitor metastatic breast cancer patients 132
Low s.c. rIL-2 doses cyclically given in advanced renal cancer patients 132
Osteoporosis and biomaterial osteointegration 132
Bioabsorbable scaffold for in situ bone regeneration. 131
Comparison between hydroxyproline (OHP) and deoxypyridinoline (DPD) in the detection of bone metastases in patints with breast cancer and benigne pathology 130
Usefulness of serum NSE and S-100 protein in patients with malignant melanoma: preliminary data 130
From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules 130
In colorectal cancer a multistep therapy with subcutaneous (s.c.) low dose recombinant interleukin-2(rIL-2),5-fluorouracil (5-FU) and leucovorin(LV) prolongs the duration of responce and overall survival of patients with inoperable metastases 128
Atherosclerosis and cancer: common pathways on the vascular endothelium 128
Preoperative histological diagnosis of palpable thyroid nodules: accuracy of aspiration needle biopsy 127
TSH levels are affected by time of blood sampling in the follow up of levothyroxine substitution therapy: preliminary report 126
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect 126
Our experience with subcutaneous (s.c.) rIL2 therapy in advanced cancer patients 125
Uselfulness of serum CEA, GICA and ferritin measurement in the postoperative follow-up of renal cancer 125
Subcutaneous (sc) low dose rIL-2 cyclically given prolongs the response to 5-FU and leucovorin (LV) in metastatic colorectal cancer 125
Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients 125
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. 125
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial 125
Serum levels of T-lymphocyte subpopulations, eosinophils, sIL-2R, neopterin and IL-4, IL-6, IL-10, IL-12 in metastatic renal and colorectal cancer patients (pts) cyclically treated with low subcutaneous (s.c.) rIL-2 124
Advanced breast cancer: an update and controversies on diagnosis and therapy 124
Comparison Between Two Different Dynamic Methods for Evaluating CEA-TPA-CA15.3 Tumor Marker ™ Panel Specificity in the Post-Operative Follow-up of Disease-Free Breast Cancer Patients: Preliminary Results 124
Early detection of colorectal cancer relapses with tumor markers 123
Emergent biomolecular markers for improving preoperative diagnosis of thyroid tumors 123
TSH levels are affected by time of blood sampling in untreated euthyroid goitrous patients. 122
In colorectal cancer a multistep therapy with subcutaneous (s. c.) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) prolongs the duration of response and overall survival of patients with inoperable metastases 122
Role of obesity , alcohol and smoking on bone health 122
Comparison between two groups of breast cancer patients submitted or not to a rational post-operative follow-up with tumor markers 121
Prognostc value of tissue vascular endothelial growth factor in primary breast cancer 121
Manual lymphatic drainage for chronic post-mastectomy lymphoedema treatment 121
Usefulness of a rationale post-operative follow-up of breast cancer with tumor markers 120
Home therapy with low-dose s.c. rIL-2 cycles to prolong the response to 5-FU and leucovorin (LV) in metastatic colorectal cancer 119
intensive post operative follow of breast cancer patients with tumors markers: accuracy of serum MCA,Ca 15,3 and CEA, TPA,CA15.3 tumor maker panel for early detection of relapse. 119
First Line Salvage Hormone Immunotherapy in Endocrine-Dependent Metastatic Breast Cancer 119
Subcutaneous (s.c.) low dose rIL-2 cyclically given increases the response rate (RR) and prolongs the response to 5-FU and LV of metastatic colorectal cancer patients (pts): an update of results 118
In breast cancer patients the post-operative follow-up with CEA-TPA-CA15.3 tumor marker panel is cost effective 118
Aspiration needle biopsy refines preoperative diagnosis of thyroid nodules defined at fine needle aspiration as microfollicular nodule 118
Effects of pulsed electromagnetic fields on articular hyaline cartilage: review of experimental and clinical studies 118
Cyclin D-1 prognostic value compared to axillary node status (N), ER, PgR, MIB-1 and p53 in breast cancer patients 2, 5 and more than 10 years after mastectomy. 117
Prognostic value of tissue vascular endothelial growth factor (VEGF) in primary breast cance 117
Methodological and clinical progress in thyroid tumor markers 117
CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. 117
181) Tumour markers improve cost-effectiveness ratio of post-operative follow-up of breast cancer patients. 116
Metastatic colo rectal cancer : a pilot study with multistep therapy. 116
Therapy following “early” detection of relapse with the CEA-TPA-CA15.3 panel after mastectomy prolongs overall survival 116
A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study 116
Cytokines in the management of high risk or advanced breast cancer: an update and expectation 116
Bone remodeling, humoral networks and smart biomaterial technology for osteoporosis 116
Von Willebrand’s factor mediates the adherence of human tumoral cells to human endothelial cells and ticlopidine interferes with this effect 115
Standardized use of serum tumor markers (TMs) for post-operative breast cancer follow-up: an impossible task? 115
Totale 13.872
Salva come PNG Salva come JPEG
Categoria #
all - tutte 64.317
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 64.317
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021727 0 0 0 0 0 45 86 165 67 103 54 207
2021/20221.942 3 157 15 79 406 312 23 79 124 37 52 655
2022/20232.324 323 178 132 220 295 372 18 188 424 9 140 25
2023/20242.001 351 251 253 114 273 346 23 52 39 21 36 242
2024/20255.567 31 237 44 352 331 411 560 365 652 839 667 1.078
2025/20263.258 308 883 715 289 445 618 0 0 0 0 0 0
Totale 24.906